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Cellular/Molecular
-Opioid Inhibition of Ca2 Currents and Secretion in
Isolated Terminals of the Neurohypophysis Occurs via
Ryanodine-Sensitive Ca2 Stores
Cristina Vela´zquez-Marrero, Sonia Ortiz-Miranda, He´ctor G. Marrero, Edward E. Custer, Steven N. Treistman,
and Jose´ R. Lemos
Department of Microbiology and Physiological Systems and Program in Neuroscience, University of Massachusetts Medical School, Worcester,
Massachusetts 01605
-Opioid agonists have no effect on calcium currents (ICa) in neurohypophysial terminals when recorded using the classic whole-cell
patch-clampconfiguration.However,-opioid receptor (MOR)-mediated inhibitionof ICa is reliably demonstratedusing theperforated-
patch configuration. This suggests that the MOR-signaling pathway is sensitive to intraterminal dialysis and is therefore mediated by a
readily diffusible second messenger. Using the perforated patch-clamp technique and ratio-calcium-imaging methods, we describe a
diffusible secondmessenger pathway stimulated by theMOR that inhibits voltage-gated calcium channels in isolated terminals from the
rat neurohypophysis (NH). Our results show a rise in basal intracellular calcium ([Ca2]i ) in response to application of [D-Ala
2-N-Me-
Phe4,Gly5-ol]-Enkephalin (DAMGO), a MOR agonist, that is blocked by D-Phe-Cys-Tyr-D-Trp-Orn-Thr-Pen-Thr-NH2 (CTOP), a MOR
antagonist. Buffering DAMGO-induced changes in [Ca2]i with BAPTA-AM completely blocked the inhibition of both ICa and high-K
-
induced rises in [Ca2]i due toMORactivation, but had no effect on-opioid receptor (KOR)-mediated inhibition. Given the presence of
ryanodine-sensitive stores in isolated terminals, we tested 8-bromo-cyclic adenosine diphosphate ribose (8Br-cADPr), a competitive
inhibitor of cyclic ADP-ribose (cADPr) signaling that partially relieves DAMGO inhibition of ICa and completely relievesMOR-mediated
inhibition of high-K-induced and DAMGO-induced rises in [Ca2]i. Furthermore, antagonist concentrations of ryanodine completely
blockedMOR-induced increases in [Ca2]i and inhibition of ICa andhigh-K
-induced rises in [Ca2]i while not affectingKOR-mediated
inhibition. Antagonist concentrations of ryanodine also blocked MOR-mediated inhibition of electrically-evoked increases in capaci-
tance. These results strongly suggest that a key diffusible second messenger mediating the MOR-signaling pathway in NH terminals is
[Ca2]i released by cADPr from ryanodine-sensitive stores.
Key words: exocytosis; ICa ; MORmodulation; NH terminals; RyR
Introduction
The -opioid receptor (MOR)-mediated inhibition of the hypo-
thalamic neurohypophysial system (HNS) becomes increasingly
evident during pregnancy, but is interrupted before parturition,
allowing for strong excitation of oxytocin cells that facilitates
birth (Russell et al., 1995; Russell et al., 2003). Corelease of
dynorphin-A, an endogenous -opioid receptor (KOR) agonist,
with vasopressin from dendrites facilitates activity-dependent
modulation of vasopressinergic neurons (Brown and Bourque,
2004; Brown et al., 2004; Roper et al., 2004; Brown et al., 2006;
Sabatier and Leng, 2007). Isolated HNS terminals demonstrate
inhibition of release in the presence of either MOR or KOR ago-
nists for both oxytocin and vasopressin (Sumner et al., 1990; Kato
et al., 1992; Russell et al., 1993); ICa is similarly inhibited (Rusin et
al., 1997; Ortiz-Miranda et al., 2003; Ortiz-Miranda et al., 2005).
The signaling mechanism and modulatory importance of MOR
and KOR activation at these presynaptic terminals and subse-
quent ICa inhibition, however, is not well understood. Given the
level of endogenous opioidmodulation in the HNS, this has con-
siderable physiological relevance.
MOR and KOR are G-protein-coupled receptors that could
potentially mediate inhibitory effects of opioids/opiates on ICa
through either a membrane-delimited or diffusible second mes-
senger pathway (Wilding et al., 1995; Soldo and Moises, 1998;
Kaneko et al., 1998; Connor and Christie, 1999; Chen et al.,
2000). The MOR-signaling pathway seems to contrast sharply
with that documented for the KOR in the same isolated neuro-
hypophysis (NH) terminals (Vela´zquez-Marrero et al., 2010).
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MORagonists did not inhibit ICawhen recorded using thewhole-
cell patch-clamp configuration, in contrast to KOR-mediated
inhibition (Rusin et al., 1997). However, MOR-mediated inhibi-
tion of ICa is demonstrated using the perforated-patch configu-
ration of the patch-clamp method (Ortiz-Miranda et al., 2005).
This strongly suggests that theMOR-signaling pathway at theNH
terminals is sensitive to intraterminal dialysis and is therefore
mediated by a readily diffusible secondmessenger. Furthermore,
unlike the KOR-mediated inhibition of ICa, MOR inhibition is
not relieved by a strong depolarizing prepulse (Vela´zquez-
Marrero et al., 2010).
Ryanodine-sensitive calcium stores have been shown to be
targets of G-protein opioid activation (Tai et al., 1992; Hauser et
al., 1996; Samways and Henderson, 2006). In isolated HNS ter-
minals, we have characterized ryanodine- and voltage-sensitive
[Ca2]i release events, known as syntillas (De Crescenzo et al.,
2004). Furthermore, the cyclic ADP-ribose (cADPr) signaling
pathway initiates a signaling cascade leading to activation of the
ryanodine receptor in vivo and subsequent release of [Ca2]i
from ryanodine-sensitive stores (Galione, 1994; Sitsapesan et al.,
1995; Morita et al., 2002). Interestingly, recent studies have
shown the cADPr signaling pathway has a significant role in oxy-
tocin (OT) release from isolatedHNS terminals (Higashida et al.,
2007; Jin et al., 2007). We propose that, in HNS terminals, acti-
vation of the MOR triggers a rise in intraterminal basal calcium
released from ryanodine-sensitive stores via activation of the
cADPr signaling cascade. This rise in [Ca2]i could lead to
calcium-dependent inhibition of ICa and subsequent inhibition
of depolarization-induced neuropeptide release.
Materials andMethods
Isolation of nerve endings. Male Sprague Dawley rats (Taconic Farms)
weighing 200–250 g were sedated using CO2 and immediately decapi-
tated. The pituitary gland was isolated as described previously (Lemos et
al., 1986; Knott et al., 2005). Briefly, after removal of the anterior and
intermediate lobes, the posterior pituitary was homogenized in 270l of
buffer at 37°C containing the following (in mM): 270 sucrose, 0.004
EGTA, and 10 HEPES-Tris buffered at pH 7.25, 298–302 mOsmol/L.
The solution containing the homogenate was plated on a 35 mm Petri
dish and carefully washed in low-calcium Locke’s solution consisting of
modified normal Locke’s (NL) containing the following (in mM): 145
NaCl, 2.5 KCl, 10 HEPES, 1.2 glucose, 0.8 CaCl2, and 0.4 MgCl2, pH 7.4,
298–302 mOsmol/L.
Electrophysiological experiments. The NH was isolated and homoge-
nized as described previously (Brethes et al., 1987; Brown et al., 2006).
Current recordings were obtained using the perforated-patch configura-
tion on isolated HNS terminals. Using an inverted microscope, the ter-
minals were identified visually by their characteristic appearance,
spherical shape, lack of nuclei, and size (5–10 m in diameter). The
pipette solution consisted of the following (inmM): 145 Cs-gluconate, 15
CsCl, 2 MgCl2, 2 NaCl, 7 glucose, and 10 HEPES, pH 7.3, 295 mOsm.
Amphotericin B at a concentration of 30 M (Sigma) was added as a
perforating agent. The bath solution consisted of the following (in mM):
145 NaCl, 5 KCl, 1 MgCl2, 10 HEPES, 10 glucose, 1.2 CaCl2, pH 7.5, in
NL. In all experiments, TTX (100 nM) was added to the bath to block
sodium influx via voltage-gated sodium channels. The pipette resistance
was 5–8 M. Pipettes were made of thin borosilicate glass (Drummond
Scientific). After perforation, the terminals were voltage clamped at80
mV. Depolarization was applied every 30 s to 0 mV for 250–300 ms. The
preparation was either continually perfused via a gravity-driven perfu-
sion or was left in a static, nonperfused bath (as noted). Agonists and
antagonists were either applied through the gravity-driven perfusion sys-
tem or added to the static bath. All experiments were performed at room
temperature (25°C). Data were acquired, stored, and analyzed using a
Pentium I computer (Gateway) and pClamp 7 software (Molecular De-
vices). Currents were corrected online using an inverted P/4 protocol.
Inactivation time constants () were obtained from single exponential
fits (Igor; Wavemetrics or PClamp6) on inward ICa for 5 ms after peak
current and 3 ms before the end of stimulus.
Calcium imaging. Freshly dissociated nerve terminals (Nordmann et
al., 1987) prepared from adult Sprague Dawley CD rats were incubated
with 2.5 M Fura-2 AM for 45 min at 37°C and thoroughly washed with
NL solution containing the following (in mM): 145 NaCl, 5 KCl, 10
HEPES, 10 glucose, 1 MgCl2, and 2.2 CaCl2, pH 7.4. Ca
2 free bath
solution contained the following (inmM): 145NaCl, 5KCl, 10HEPES, 10
glucose, 0.0002 EGTA, and 1 MgCl2, pH 7.4, and gave a calculated free
[Ca2] of zero. Cytosolic [Ca2] was determined with ratiometric indi-
cator Fura-2 AM-loaded terminals. Calibration of Fura-2 was done both
in vitro using the Invitrogen Calcium Calibration Buffer Kit (catalog
#F-6774) and in situ using predetermined [Ca2]free buffered solutions
on terminals loaded with Fura-2 AM and using the Br-A23187 divalent
cation ionophore. The Kd was calculated from a plot generated by scan-
ning the ratio of the emission at the two corresponding wavelengths
against [Ca2]free across the zero to saturating [Ca
2]free concentra-
tions. The results were plotted as a double log of the calcium response
resulted in a straight line, with the x-intercept being equal to the log of the
apparentKd indicator, which was determined under in situ conditions to
be 200 nM across the physiologically relevant concentration rage of
0–35 M [Ca2]free. The calculations were performed as described pre-
viously (Grynkiewicz et al., 1985). Resting values for global cytosolic
[Ca2] in the presence and absence of extracellular Ca2were 73.3 6.9
nM (n  12) and 46.2  7.5 nM (n  8), respectively, and these values
demonstrated a statistically significant difference. In all cases, changes in
[Ca2]i were determined by measuring total calcium.
Fluorescence images using Fura-2 AM as a calcium indicator were
viewed with a Nikon Diaphot TMD microscope using a Zeiss Plan-
NEOFLUAR 100 oil-immersion lens and fitted with a Photometrics
SenSys CCD camera. The camera was interfaced to the inverted micro-
scope adapted with a Chroma 71000A Fura2 filter cube. The terminals
were excited using a Xenon arc lamp within a Lambda DG4 high-speed
filter changer (Sutter Instruments) with the appropriate filters (340 and
380 nm wavelengths). Intraterminal emission of Fura-2 Ca2 indicator
was gathered at 510 nm wavelength. Fluorescent images were acquired
and processed with Axon Imaging Workbench 2.1 software (Molecular
Devices).
Capacitance measurements. Freshly dissociated terminals (Nord-
mann et al., 1987) from adult Sprague Dawley CD rats weighing
200–250 g were plated in NL solution with 1.2 mM CaCl2. Tight seal
“whole terminal” recordings were obtained using the perforated-
patch configuration described in Electrophysiological experiments,
above. The pipette resistances ranged from 5 to 8 M. Perforation of
the terminals’ membrane was obtained by adding 30 M amphoteri-
cin B (Sigma) to the pipette solution containing the following (in
mM): 145 Cs-gluconate, 15 CsCl, 5 NaCl, 2 MgCl2, 7 glucose, and 10
HEPES pH 7.3. The bath solution contained the following (in mM):
145 NaCl, 5 KCl, 1 MgCl2, 10 HEPES, 10 glucose, and 1.2 CaCl2 or 0.2
EGTA, pH 7.5. Capacitance measurements were obtained using the
piecewise linear method (Knott et al., 2007). The changes in capaci-
tance induced by a depolarizing pulse (750 ms duration) were mea-
sured 1 s after cessation of stimulus to avoid interference of stimulus
“end-tail” effects. These stimulus-induced capacitance changes were
measured for isolated terminals (perforated-patch) using the piece-
wise method (Neher andMarty, 1982; Lindau and Neher, 1988; Gillis,
1995). Briefly, the method consists of applying a sinusoidal voltage of
low amplitude to the sample (to avoid voltage-elicited channel cur-
rents) and obtaining the phase shift of the resultant sinusoidal cur-
rent. Changes in this phase shift (“locked-in”) are used in a formula
(computer software that emulates a lock-in amplifier) for the deter-
mination of the capacitance changes (i.e., the capacitance that would
cause such change of phase shift). The method is sensitive to very
small changes in capacitance and, in practice, large baseline capaci-
tance and resistance (series) transients must be compensated (i.e.,
null) before measuring any small capacitance change. In this partic-
ular case, the parameters used were a sine wave of 1000 Hz at25 mV
(approximately the holding potential), with the program reporting a
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capacitance averaged for every 30 points (24 s sampling rate). The
current was filtered at a bandwidth of 5000 Hz.
Statistical comparisons. In all cases, data are reported as mean SEM;
n indicates the number of terminals. Statistical analysis was performed
using either a Student’s t test or a one-way ANOVA followed by a Dun-
nett’s posttest. The criterion for significance in all cases was p	 0.05.
Results
MOR but not KOR agonist elicits a rise in basal intraterminal
[Ca2]
To determine whether intraterminal Ca2 ([Ca2]i) was part of
a diffusible secondmessenger pathwaymediating opioid receptor
signaling in isolated HNS terminals, we monitored it in response
to both MOR and KOR activation. Fura-2 AM ratio calcium
imaging of isolated HNS terminals showed a significant inhibi-
tion of high-K-induced rises in [Ca2]i when treated with ei-
ther MOR agonists (Fig. 1A,B) or KOR agonists (Fig. 2C).
Furthermore, pretreatment with 100 nM DAMGO (a MOR ago-
nist) alone at either 2.2 (Fig. 1A,B) or 0 mM (Fig. 1C,D) external
calcium ([Ca2]o) elicited a rise in basal
[Ca2]i. This did not occur when termi-
nals were pretreated with 100 nM U50488
(a KOR agonist) or puffed with control 0
mM [Ca2]o NL (Fig. 1C). Application of
the MOR antagonist CTOP (Fig. 1D)
blocked the DAMGO-induced rise in
basal [Ca2]i. Changes in basal intrater-
minal calcium concentration were 26.9
0.8 nM by 100 nM DAMGO in 2.2 mM
[Ca2]o NL and (28.7 5.1 nM) in 0 mM
[Ca2]o with 100 nM DAMGO. Differ-
ences in [Ca2]i were3.3 5.2 nM due
to 100 nMU50488, controlwas2.4 3.4
nM, and 100 nM DAMGO in the presence
of CTOP was1.8 1.0 nM (all in 0 mM
[Ca2]o). Control applications (Fig. 1C)
caused an artifactual drop in [Ca2]i,
which may be an inherent factor in all
treatment applications and could there-
fore lead to an underestimation of the
DAMGO-induced rise in [Ca2]i. Control
baseline [Ca2]i averaged 71.6 15.7 nM.
MOR- but not KOR- mediated
inhibition is blocked by intraterminal
calcium buffering
To determine whether the rise in
[Ca2]i due toMOR agonist application
is essential for subsequent inhibition of
ICa, we partially buffered [Ca
2]i using
BAPTA-AM andmonitored the effects on
both ICa and high-K
-induced rises in
[Ca2]i. Empirically determined incuba-
tion periods of 5–10 min using low con-
centrations (10 M) of BAPTA-AM were
followed by a brief wash. Using this pro-
cedure, BAPTA-AM buffered DAMGO-
induced rises in intraterminal calcium
from 22.7 2.4 nM down to 0.2 0.5 nM
(Fig. 2A). However, this concentration of
BAPTA-AM did not block total high-K-
induced rise in [Ca2]i (Fig. 2B,C). Ef-
fects on both high-K-induced rises in
[Ca2]i and ICa were measured for both
MOR- and KOR-mediated inhibitions using the same concentra-
tion of BAPTA-AM for identical incubation periods. All measure-
ments were made as either changes in basal [Ca2]i or as a
percentage of control. Control measurements were under identical
conditions without opioid/opiate treatments. High-K-induced
rises in [Ca2]i in the presence of 100 nM DAMGO were 54.1 
3.4% of control responses. High K in the presence of 100 nM
U50488 was also inhibited to 70.9  2.8% of controls (Fig. 2C).
However, after incubation with 10 M BAPTA-AM, terminals ex-
posed to100nMDAMGOshowednosignificant inhibition(109.9
12.8%) of the high-K-induced rise in [Ca2]i (p 0.05), as op-
posed to without BAPTA-AM treatment (p  0.002). In contrast,
inhibition (78.52.8%)of thehighK responseby100nMU50488
remained the samewithversuswithoutBAPTA-AMtreatment (p
0.3). Baseline [Ca2]i before high K
 was not statistically different
(p 0.16) with (77.9 12.8 nM) versus without (86.5 27.5 nM) 5
min preincubation by 10 M BAPTA-AM. Total [Ca2]i was not
significantly changed (see legend to Fig. 2). Furthermore, mM
Figure 1. MOR but not KOR agonists trigger a rise in basal [Ca 2]i preceding MOR-mediated inhibition of high-K
-induced
rise in [Ca 2]i.A, Images of a Fura-2 AM-loaded single terminal10 s apart challengedwith high-K
 (HiK) in 2.2mM [Ca 2]o
for 5 s with and without 100 nM DAMGO preexposure. B, Plot of changes in [Ca 2]i over time of a different single isolated HNS
terminal loadedwith Fura 2-AM: high K (as labeled) exposures for 5 s and DAMGO (as labeled) pretreatment for 10 s followed by
high K in the presence of 100 nMDAMGO (as labeled). Double forward slashes in x-axis represent 30 s breaks in image acquisition
to allow recovery from high K treatment. C, [Ca 2]i change from baseline in response to 100 nM U50488, 100 nM DAMGO, and
control treatment containing modified NL without Ca 2 (as labeled); n 5 terminals. D, Rise in [Ca 2]i due to 100 nM DAMGO
application is blocked in the presence of 100 nM CTOP (as labeled); n 4 terminals. Asterisks (*) represent statistical differences
( p 0.002).
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BAPTA is needed to affect highK peaks in
[Ca2]i. Therefore, changes in responses to
opioids cannotbe attributed to initial differ-
ences in baseline [Ca2]i.
Effects on calcium currents
Buffering [Ca2]i also blocked inhibition
of ICa byMORbut not KOR agonists. Ter-
minals treated with 100 nMDAMGOwere
82.2 4.0% of control currents and were
88.7 2.3%with 100 nMU50488 (Fig. 3).
After preincubation with 10 M BAPTA-
AM, 100 nM DAMGO elicited no inhibi-
tion, with ICa being 98.9  1.2% of
control. Exposing BAPTA-AM-treated
terminals to 100 nMU50488 again showed
no change in KOR-mediated inhibition,
with ICa remaining at 78.8 4.9% of con-
trols. Statistical analysis determined no
significant difference (p 0.09) between
terminals treated with 100 nM U50488,
with versus without BAPTA-AMpreincu-
bation (Fig. 3C). There was, however, a
statistically significant difference (p 
0.001) between terminals treated with
100 nM DAMGO with versus without
BAPTA-AM preincubation.
cADPr pathway
Because activation of the MOR-induced rise in [Ca2]i appears
to be essential in mediating MOR inhibition, we investigated
whether cADPrwas part of this receptor’s intraterminal signaling
pathway. We examined the effects of the membrane-permeant
cADPr antagonist 8-bromo-cyclic adenosine diphosphate ribose
(8Br-cADPr) on MOR-mediated inhibition of both high-K-
induced rises in [Ca2]i (Fig. 4A,B) and ICa (Fig. 4C,D). Control
high-K-induced changes in [Ca2]i were 457.1 13.5 nM, but
in the presence of 100 nMDAMGO high-K-induced changes in
[Ca2]i decreased to 392.7 19.6 nM (p 0.04). After incuba-
tion with 100 nM 8Br-cADPr, terminals exposed to 100 nM
Figure 3. BAPTA-AM preincubation relieves MOR- but not KOR-mediated inhibition of calcium currents. A, Representative
bariumcurrents of an isolatedHNS terminal; control currents (black), 100nMDAMGO (gray), andwash (dashed-black).B, The same
isolated HNS terminal: control is preincubated in 10M BAPTA-AM (black) compared with trace preincubated in BAPTA-AMwith
100 nM DAMGO (gray) and wash (dashed-black). C, Bar graph quantifying peak barium currents (n 4) as percentage of control
current without any opioid treatment (as labeled). Asterisk (*) represents statistically significant differences ( p 0.001).
Figure2. BAPTA-AM relieves rise in basal [Ca 2]i due toMORagonist andMOR- but not KOR-mediated inhibition of high-K
-induced rise in [Ca 2]i.A, Bar graphof absolute change in [Ca
2]i
frombaseline in thepresence of 100nMDAMGOwith andwithout a 5minpreincubationwith 10MBAPTA-AM, in 2.2mM [Ca 2]o. PreincubationwithBAPTA-AMcompletely blocks the rise in basal
[Ca 2]i due to-opioid agonist. Asterisk (*) represents statistical difference ( p0.004) between100nMDAMGOand100nMDAMGOpretreatedwith 10MBAPTA-AM(n3).B, Plot of changes
in [Ca 2]i of a single HNS terminal loaded with Fura-2 AMwith and without a brief 10M BAPTA-AM preincubation treated with high K
 (HiK) or high Kwith 100 nM DAMGO (premixed for
a simultaneous exposure) in NL solution. Double forward slashes in x-axis represent 30 s breaks in image acquisition to allow high K treatment to recover. C, Bar graph quantifying changes in
[Ca 2]i in response to high K, and high K
with 100 nM DAMGO or 100 nM U50488 with and without BAPTA-AM preincubation (n 4). Asterisk (*) represents statistically significant differences
( p0.001). Total [Ca 2]i risedue tohighK
arenot significantly ( p
0.05) changedwithBAPTA,probablybecausemMBAPTA isneeded toblock thehighK response (Stuenkel andNordmann,
1993).
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DAMGO exhibited only a change in [Ca2]i of 425.9 11.3 nM
in response to high K, similar to those in 100 nM 8Br-cADPr
without DAMGO treatment (427.2 8.9 nM). Statistical analysis
determined no significant difference (p  0.43) in high-K-
induced changes in [Ca2]i between terminals treated with 100
nM 8Br-cADPr with versus without 100 nM DAMGO treatment
(Fig. 4A,B).However, in terminals not preincubatedwith 100 nM
8Br-cADPr, there was a statistically significant difference (p 
0.0004) in high-K-induced changes in [Ca2]i between termi-
nals treated with versus without 100 nM DAMGO, as was ob-
served previously. Interestingly, basal [Ca2]i without 100 nM
8Br-cADPr preincubationwas 79.2 4.0 nM; after preincubation
with 100 nM 8Br-cADPr, it was 68.9 2.8 nM (n 8) and these
baselines were statistically different (p 0.02).
Terminals treated with 100 nM DAMGO resulted in ICa mea-
suring 76 2.4% of control currents (Fig. 4C,D). After preincu-
bation with 100 nM 8Br-cADPr, however, 100 nM DAMGO
treatments now showed a partial relief of inhibition, with ICa at
90  2.1% of control. Intraterminal calcium followed a similar
trend, with 8Br-cADPr significantly (p  0.004) blocking the
DAMGO-induced rise in [Ca2]i (Fig.
5A), suggesting that the cADPr pathway is
involved in MOR signaling.
MOR effects are blocked by ryanodine
receptor antagonist
We next addressed whether the release of
[Ca2]i due to MOR activation was from
ryanodine-sensitive intraterminal stores.
The pharmacology of the ryanodine re-
ceptor indicates that 10–100 M concen-
trations of ryanodine can block ryanodine
channel activity (Coronado, Morrissette
et al., 1994; Ehrlich, Kaftan et al., 1994).
Therefore, we tested the effects of 100 M
ryanodine on DAMGO-induced rises in
basal [Ca2]i (Fig. 5A) and its inhibition
of high-K-induced rises in [Ca2]i (Fig.
5B,C), ICa (Figs. 6, 7), and electrically in-
duced capacitance changes (Fig. 7).
DAMGO-induced changes in basal
[Ca2]i were 21.3 3.2 nM, but after pre-
incubation with 100 M ryanodine (Fig.
5A), these were significantly (p 0.0002)
reduced to 0.1  0.8 nM. Likewise,
DAMGO-induced changes in basal
[Ca 2]i were blocked by 100 nM 8Br-
cADPr (Fig. 5A).
Control high-K-induced changes in
[Ca2]i were 219.9 21.4 nM. In the pres-
ence of 100 nM DAMGO, high-K-
induced changes in [Ca2]i were 112.7
8 nM, which represents 51% of the control
response (Fig. 5B,C). After incubation
with 100 M ryanodine, terminals ex-
posed to 100 nM DAMGO now showed a
change in [Ca2]i of 236.8  8.2 nM in
response to high K, similar to controls
without DAMGO (209 13.4 nM) in the
presence of 100 M ryanodine. There was
no significant difference (p  0.11) in
high-K-induced changes in basal [Ca2]i
between control terminals in 100 M ryan-
odine and those in 100Mryanodine treatedwith 100nMDAMGO.
However, therewas a statistically significant difference (p 0.01) in
high-K-induced changes in [Ca2]i between terminals treated
with versuswithout 100 nMDAMGO,whichwere not preincubated
with 100 M ryanodine. Control baseline [Ca2]i was 62.2 11.3
nM and 76.1 11.5 nM after preincubation with 100M ryanodine
(n 3). Therewas no statistical difference betweenbaseline [Ca2]i
with versus without 100M ryanodine incubation (p 0.06).
Inhibition of ICa by 100 nM DAMGO was measured as per-
centage of controls. Calcium currents treated with 100 nM
DAMGO (Fig. 6A) were inhibited to 76.3  1.8% of control
currents (Fig. 7C). During incubation with 100 M ryanodine
(Fig. 6B), ICa treated with 100 nMDAMGO showed no significant
inhibition, being 94.6 2.5% of controls (n 6). There was no
statistically significant difference (p 0.10) between terminals in
the presence of 100 M ryanodine with and without 100 nM
DAMGO.
Inactivation of ICa via Ca
2-dependent inactivation could be
reflected in the time constants of inactivation of the total re-
corded currents. We therefore measured the time constants of
Figure 4. cADPr antagonist relieves MOR-mediated inhibition of high-K-induced rise in [Ca 2]i and inhibition of calcium
currents. A, Consecutive images of a Fura-2 AM-loaded single HNS terminal10 s apart challenged with high K (HiK) in 2.2
mM [Ca 2]o for 10 s with and without 100 nM DAMGO and with and without pretreatment with 100 nM 8Br-cADPr. B, Bar graph
summarizing the absolute changes in [Ca 2]i from baseline in response to high K
 challenges with and without 100 nM DAMGO
and with and without incubation with 100 nM 8Br-cADPr (n 8 each). C, Representative ICa of an isolated HNS terminal; control
currents (black), 100 nM DAMGO (gray), recovery (dashed-gray), and 150 nM 8Br-cADPr w/100 nM DAMGO (dashed-black). D, Bar
graph quantifying the peak ICa (n 6) as percentage of control currentwithout DAMGO. Calcium currentswith 100 nM DAMGO (as
labeled) andwith 100 nM DAMGO preincubatedwith 150 nM 8Br-cADPr (as labeled). Asterisk (*) represents statistically significant
differences ( p 0.02). Interestingly, 8Br-cADPr had no significant ( p
 0.05) effect on its own.
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inactivation of the ICa (see Materials and
Methods) under control (no opioid or ry-
anodine), 100 nMDAMGO, 100M ryan-
odine, or 100 M ryanodine with 100 nM
DAMGO conditions (Fig. 7D). The re-
sults were plotted as percentage of con-
trols. The average inactivation time
constant tau () for the control currents
(SE) was 137.0  25.6 s. Calcium cur-
rents remaining in the presence of
DAMGO showed slower inactivation ki-
netics that were 133  2.6% of control.
Currents with 100 nMDAMGO treatment
had a   182.14  8.7 ms, which is dif-
ferent from control values (p  0.001).
Most interestingly, terminals treated with
100 nM DAMGO and 100 M ryanodine
had a   131.67  12.8 ms. In the pres-
ence of 100 M ryanodine, these ’s were
105.4 3.9% (p 0.77), and, in the pres-
ence of 100 M ryanodine and 100 nM
DAMGO, they were 96.1  3.7% (p 
0.22).
Effects on capacitance
Reduction of depolarization-induced neuropeptide release has been
showntobedue toMOR-mediated inhibitionof ICa (Ortiz-Miranda
et al., 2010, 2005). IfMOR-mediated inhibitionof ICa canbeblocked
by 100 M ryanodine, will it also block the MOR-mediated reduc-
tion in neuropeptide release? To address this question, we moni-
tored changes in exocytosis/endocytosis reflected as capacitance
changes in individual HNS terminals (see Materials and Methods).
Changes in capacitance inperforated-patch-clamped isolated termi-
nals in response to rectangularpulsedepolarizations are inhibitedby
100 nM DAMGO (Fig. 7A). This inhibition is almost completely
reversed by 100 nM CTOP (data not shown), indicating that it is
mediated by activation of the MOR. In the presence of 100 nM
DAMGO, capacitance changes were 43.8  8.2% of controls (Fig.
7A,B). When incubated in 100 M ryanodine, capacitance changes
were 102.9 3.5% of controls. Application of 100 nM DAMGO in
thepresence of 100Mryanodine resulted in 98.2 2.7%of control
capacitance changes and was statistically no different from controls
(p 0.99) or capacitance changes in the presence of 100 mM ryan-
odine alone (p  0.16). Time constants (two exponential fits) for
each capacitance changewere not significantly different between the
treatments, allowing us to conclude that these effects were not on
Figure 6. RyR antagonist relievesMOR inhibition of calcium currents.A, Representative ICa of an isolated HNS terminal; control
currents (dashed-black), 100 nM DAMGO (black), and wash (gray). B, The same isolated HNS terminal with the wash (gray) as
control current followed by current trace in the presence of 100M ryanodine (dashed-black) and current trace in the presence of
100M ryanodine with 100 nM DAMGO (dashed-black).
Figure 5. DAMGO-induced release of intraterminal calcium is reduced by either 8Br-cADPr or ryanodine, which relieves MOR- but not KOR-mediated inhibition of high-K-induced rises in
[Ca 2]i. A, [Ca
2]i change from baseline in response to 100 nM DAMGO, and 100 nM DAMGO with100 nM 8Br-cADPr (as labeled); n 21 terminals. Rise in basal [Ca
2]i due to 100 nM DAMGO
application is reduced in the presence of 100M ryanodine (as labeled);n6 terminals. Asterisks (**) represent statistical differences ofp0.0002, and (*) represent statistical differences ofp
0.004.B, Trace of changes in [Ca 2]i in an HNS terminal with andwithout 100M ryanodine preincubation and challengedwith high K
 (HiK) and high Kwith 100 nM DAMGO (premixed for
a simultaneous exposure). C, Bar graph quantifying absolute changes in [Ca 2]i in response to high K
 control (without opioid or other treatment for each series; gray bars) and high Kwith 100
nMDAMGO (n 7) or 100 nMU50488 (n 5)with andwithout 100M ryanodine plotted as absolute change in [Ca 2]i (bars as labeled). Asterisk (*) represents statistically significant differences
( p 0.001).
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endocytosis alone. Furthermore, we have shown previously (Ortiz-
Miranda et al., 2003; Ortiz-Miranda et al., 2005) that AVP/OT re-
lease induced by high K is inhibited by DAMGO, indicating that
the net effect is inhibition of exocytosis. Therefore, antagonist con-
centrations of ryanodine are able to block inhibitionof exocytosis by
MOR activation. Nevertheless, effects on endocytosis are also possi-
ble (see Discussion).
Discussion
The present study demonstrates that, in isolated HNS terminals,
activation of the MOR elicits release of intraterminal Ca2 from
ryanodine-sensitive stores. MOR-mediated inhibition of ICa and
of high-K-induced rises in [Ca2]i can
be blocked by antagonist concentrations
of ryanodine and reduced by inhibition of
the cADPr pathway. Changes in the inac-
tivation kinetics of ICa in the presence of
MOR agonists suggests that release of
intraterminal Ca2 could be responsible
for Ca2-dependent inactivation of ICa.
However, because stores cannot be de-
pleted and ryanodine receptor (RyR) KO
animals are not viable (De Crescenzo et
al., 2012), it is not possible to prove this.
Nevertheless, showing that BAPTA, ryan-
odine and 8Br-cADPr are all capable of
blocking DAMGO’s effects is strong evi-
dence in support of the role of intrater-
minal Ca 2 stores in mediating MOR
inhibition.
Furthermore, MOR-mediated inhibi-
tion of capacitance in individual terminals
can also be blocked by antagonist concen-
trations of ryanodine. These data support
the hypothesis (Fig. 8) that MOR activa-
tion leads to the release of Ca2 from
ryanodine-sensitive stores via activation
of the cADPr pathway, possibly leading to
Ca2-dependent inactivation of ICa and
subsequent inhibition of depolarization-
secretion coupling (DSC).
cADPr pathway and ryanodine-
sensitive stores in HNS terminals
Oxytocin secretion is most sensitive to
MOR-mediated inhibition (Wright and
Clarke, 1984; Bicknell et al., 1985; Zhao et
al., 1988; Leng et al., 1992; Russell et al.,
1995; Ortiz-Miranda et al., 2005). Vaso-
pressin release, although responsive to
MOR-mediated inhibition, is less sensi-
tive to MOR agonists (Ortiz-Miranda et
al., 2003). Interestingly, in HNS termi-
nals, blocking cADPr signaling was shown
to attenuate high-K induced rises in
[Ca2]i, but only inhibited OT release
from isolated terminals (Higashida et al.,
2007; Jin et al., 2007). This strongly sug-
gests that the cADPr pathway is both pres-
ent in OT terminals and linked to
neuropeptide release and thus may be re-
sponsible for OT-terminal-heightened
sensitivity to MOR-mediated inhibition
(Fig. 8).
CD38 is a catalyst for the formation of cADPr and nicotinic acid
adenine dinucleotide phosphate by ADP-ribosyl cyclase from
NAD andNADphosphate (Lee, 1998). Both are known to release
Ca2 from intracellular ryanodine-sensitive pools as part of a
second messenger-signaling pathway. In studies monitoring
depolarization-induced OT secretion in murine NH terminals (Jin
et al., 2007),CD38/mice showedsevere andselective impairment
of OT release. Currently, this contribution of the cADPr pathway to
depolarization-induced responses appears to be in conflict with our
results showing the cADPr pathway mediating ICa inhibition trig-
gered by activation of theMOR (Fig. 8). Although it is clear that the
Figure 7. RyR antagonist relieves MOR inhibition of depolarization-induced exocytosis. A, Capacitance measurements of a
single terminal in the absence (black) and presence of 100 nM DAMGO (dashed-black) and of 100 M ryanodine with 100 nM
DAMGO (gray) using a square pulse of 80mV for a duration of 750ms. Inset shows the currents obtained from the actual stimulus
(same indicators). The generalized conductance changes (G) are shown for reference. Dashed gray lines represent the zero-change
baselines. Capacitancemeasurements in the presence of DAMGOwere statistically significantly different fromall other treatments
( p 0.002; n 5). B, Bar graph quantifying changes in stimulus-induced capacitance (n 3) measured 1 s after cessation of
stimulus in thepresenceof 100nMDAMGOand100M ryanodinewith100nMDAMGOplottedaspercentageof controlwithout any
drug treatment (as labeled). C, Bar graph quantifying peak ICa (n 5) as a percentage of control peak current without drug
treatment (as labeled).D, Bar graph quantifying the inactivation time constants of ICa (n 5) as a percentage of controls without
treatment (as labeled). For the decay time (inactivation), the fit was made between 5 ms after peak (to avoid multiple exponen-
tials) and 3 ms before the end of stimulus (to avoid transient artifacts). Asterisks (*) represent statistically significant differences
( p 0.009).
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cADPrpathway inHNSterminals canmod-
ulate the depolarization-induced response,
our results suggest that it may do so dif-
ferentially depending on the compart-
ments/circumstances in which the
pathway is activated. For example, in our
model (Fig. 8), MOR activation of the
cADPr pathway releases Ca2 from
RyRs and, via PK/PP, leads to inactiva-
tion of nearby, closed VGCCs. Upon de-
polarization, these VGCCs would not be
available for activation, leading to less
neuropeptide release. Direct activation of
a specific pool of intraterminal calcium
stores during depolarization-induced re-
sponses, however, via the cADPr pathway
could directly target specific release sites,
resulting in potentiation of the response.
We have previously demonstrated Ca2
sparks or “syntillas” in murine HNS ter-
minals that are both ryanodine and volt-
age sensitive (De Crescenzo et al., 2004,
2006). Syntillas result from the activation
of both type-1 and type-2 RyRs. Presum-
ably, the type-1 RyR confers the voltage
sensitivity via direct interaction with di-
hydropyridine receptors (De Crescenzo et
al., 2006), as documented in skeletal mus-
cle (Schneider andChandler, 1973; Inui et
al., 1987). The cADPr pathway may assist
in amplifying this direct effect in HNS terminals during DSC.
Inhibition of voltage-dependent release of calcium from
ryanodine-sensitive storesmay account for the inhibition of both
the depolarization-induced rise in [Ca2]i and oxytocin release
observed in the presence of 200 M ryanodine, as described pre-
viously (Jin et al., 2007). However, Jin et al. (2007) showed no
effects onAVP release, whichwould be consistentwith our lack of
capacitance changes in the presence of 100 M ryanodine alone
(Fig. 7A). Activation of the cADPr-pathway via the MOR could
result in a release of [Ca2]i from a different subset of ryanodine
receptors (see model in Fig. 8) that both temporally and spatially
result in calcium-induced inhibition of ICa and subsequent inhi-
bition of neuropeptide release. The relative ratio of these effects
would determine the net impact on DSC (see model in Fig. 8
describing the transduction mechanisms thought to underlie the
MOR and KOR effects seen in this system in relation to oxytocin
release).
There are some other important considerations thatmust also
be addressed to interpret our results. First, the concentration of
8Br-cADPr used in our study was 100 nM, in contrast to the 100
Mused in previous studies (Jin et al., 2007). Preliminary calcium
imaging of rat isolated HNS terminals shows a significant rise in
basal [Ca2]i in the presence of higher (100–300M) concentra-
tions of 8Br-cADPr (data not shown),which does not occur at the
100 nM concentration. This could theoretically have the same
effects as those seen for MOR activation, leading to subsequent
calcium-dependent inactivation of ICa and attenuated neuropep-
tide release. Therefore, the presence of 8Br-cADPr at higher con-
centrations would, by itself, saturate the calcium-induced
inhibitory response in the HNS rat preparation.
Furthermore, IP3 receptor effects have been observed in NH
terminals (Cazalis et al., 1987) and, because they often work in
concert with RyRs, there could also be such a role for IP3
receptors.
MOR effects on calcium currents and subsequent release
In cardiac tissue, changes in [Ca2]i can lead to inactivation of
VGCCs (Morad, 1995). Calcium-dependent inactivation of
VGCCs in HNS terminals has been demonstrated previously
(Branchaw et al., 1997; Wang et al., 1999). Similarly, -opioid
inhibition of ICa results in a decreased rate of inactivation of
the remaining ICa during a depolarizing stimulation pulse
(Fig. 7D). Presumably, the fraction of ICa remaining after
calcium-dependent inactivation represents currents shielded
from the effects of intraterminal Ca 2. It is also possible that a
Ca2-dependent process (e.g., protein kinase or phosphatase;
Ortiz-Miranda et al., 2010) is involved (see model legend in
Fig. 8). Although the mechanism underlying this phenome-
non is unknown, VGCCs in terminals are unique in other
ways. The N-type Ca2 channels in the NH (Lemos and Now-
ycky, 1989; Wang et al., 1993) have lower single-schannel con-
ductance and more rapid inactivation kinetics than those
observed for conventional somatic channels (Bean, 1989;
Wang et al., 1993). In our model, release of calcium from
ryanodine-sensitive stores may lead to calcium-dependent in-
activation of VGCCs and a reduced ICa. The remaining ICa has
slower inactivation kinetics, possibly indicating that they are
only exhibiting Ca2-independent inactivation (Fig. 7D).
This reduction in ICa would lead to decreased exocytosis (Fig.
7A) of neuropeptides from the terminals.
We cannot say unequivocally that exocytosis is the sole con-
tributor to the effects of MOR modulation of ICa on release dy-
namics that we report here. It is possible that our observations
include effects on endocytosis or on exo-endocytosis (e.g., in-
creases in “kiss and run”). However, we believe the exocytotic
Figure 8. Model for opioid modulation of calcium currents. Activation of the MOR initiates cADPr signaling, presumably via Gq
activation of ADP-rybosyl cyclase/CD38 complex catalyzing the conversion of NAD into cADPr. Cyclic-ADPr subsequently leads to
activation of RyRs on neurosecretory granules (NSGs) in the terminals. Release of the diffusible second messenger Ca 2 from
ryanodine-sensitive stores subsequently results in Ca 2-dependent inactivation of closedVGCCs possibly via protein kinases (PKs)
and/or protein phosphatases (PPs). In contrast, activation of the KOR initiates Gi,o -protein dissociation from G subunits.
Gmediates membrane-delimited voltage-dependent inhibition of ICa via direct interaction with the closed or resting channel.
Inhibition () of ICa would lead to decreased release of OT. In contrast, Ca
2-induced Ca 2-release from RyR stores would
stimulate () OT secretion (Jin et al., 2007).
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component is amajor contributor to themodulation we observe.
Among other evidence, the most compelling to suggest this is the
fact that when we blocked endocytosis using Ba2 instead of
Ca2 (data not shown), DAMGO still inhibited the elicited ca-
pacitance changes.
Conclusions
Diffusible second messenger amplification of MOR signaling via
cADPr-mediated release of Ca2 from a ryanodine-sensitive
stores seems well suited for regulating OT release during the rel-
atively long period of gestation. It is during this time that endog-
enous MOR-mediated inhibition of release accumulates OT, but
is then interrupted during parturition and subsequent lactation
(Russell et al., 1989; Douglas et al., 1995; Russell et al., 1995;
Ortiz-Miranda et al., 2003). Interestingly, opioid-receptor-
induced Ca2 mobilization has also been observed in both mu-
rine astrocytes (Hauser et al., 1996) and isolated rat ventricular
myocytes (Tai et al., 1992). Intraterminal calcium release and its
associated Ca2microdomains likely have a wide range of possi-
ble targets and subsequent effects on depolarization-secretion
coupling (Berridge, 2006; Oheim et al., 2006). Therefore,
ryanodine-sensitive stores in HNS terminals may prove to be
bimodal regulators of release depending on the physiological cir-
cumstances. Given the emerging role of ryanodine-sensitive
stores and the cADPr signaling pathway in the CNS, our results
represent an important contribution to our understanding of
their physiological role in presynaptic terminals during DSC.
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